Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Clinical trial NCT04607954 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04607954
Sponsor: Mayo Clinic
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Platinum-Resistant Lung Small Cell Carcinoma Platinum-Sensitive Lung Small Cell Carcinoma Recurrent Extensive Stage Lung Small Cell Carcinoma Refractory Extensive Stage Lung Small Cell Carcinoma

Start date: 2020-12-04
Primary completion: 2026-09-01
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.